Merck's long-term data shows sustained survival benefits with KEYTRUDA in lung cancer
PositiveFinancial Markets

Merck has released long-term data demonstrating that its cancer treatment, KEYTRUDA, continues to provide significant survival benefits for patients with lung cancer. This is important because it reinforces the effectiveness of KEYTRUDA as a vital option in cancer therapy, potentially improving the quality of life for many patients facing this challenging disease.
— Curated by the World Pulse Now AI Editorial System